Accent Microcell Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/868px1idpyzei1shla5tasgr.pdf

Key Takeaways


Phase 1 Commercialization: The Critical Path

Mr. Nitin: "due to election the officials were inactive from last 15 days that caused the delay but we submit the file again till June 25th file it will be clear."

Product Mix & Margin Trajectory

Accent Microcell Ltd.: "It will be prudent enough to assume going ahead, as we are going ahead with more premium range of products, so it is prudent enough to assume that the blended profit margins are going to increase by, say, at least 2-3 percentage."

CCS: The Differentiated Technology Bet

Accent Microcell Ltd.: "This technology took us almost 8 years of R&D to develop. After 8 years of R&D we are successfully bringing this product to the market."

Trading Volumes: Strategic Bridge or Margin Anchor

Accent Microcell Ltd.: "it was mere to encase the business opportunity that any businessman... it is very prudent for a businessman to ensure that the existing customer base remains with the, say, the... say, it is a long process, stability approval and all those stuffs, and to get the customer on board."

Unit Economics & Cost Structure


Phase 2 & Beyond: The Capacity Roadmap

Accent Microcell Ltd.: "Sir, it was an... it was a kind of an, management, discretion, and we completely understand about the benefit of the leverage as well, but in order to gain competitive advantage, or at an early stage, we opted to go for right issue instead of debt."

Guidance & Commitments

CommitmentSpecificsTimeline
CTO license clearanceFile submitted; clearance expected by June 25thJune 2026
Phase 1 commercial productionStart production once CTO received; 20–25 days of trial runs needed for CCSQ2 FY27 (post-approvals)
Phase 1 first-year utilization50–60% of peak capacity on a per-day basis, over 9 months of productionFY27
Phase 1 peak revenueApproximately ₹150 cr at full capacity, plus/minus 5–10%At peak utilization (undated)
Phase 2 commercializationDelayed from H2 FY27 to H1 FY28; conservative timeline sharedH1 FY28
Trading volume reductionSubstantial decrease expected once Phase 2 goes liveH1 FY28 (conditional on Phase 2)
Premium product shareGradually increasing from 13% to 16–17%FY27
Blended margin improvementAt least 2–3 percentage point increase as premium mix risesUndated (trend-based)
Working capital normalizationIf not by H1 FY27, surely by FY27 endFY27
Distributor vs direct sales mixRemain around 85–15%Ongoing

Key Metrics

MetricQ4 FY26
Revenue from operationsFigures uploaded with NSE portal, YoY increase in revenue, EBITDA, PAT margins, and PAT
Export share of revenue63%, up from 53% last year
Total sales volume15,000 metric tons in FY26
Installed capacity (both plants)10,000 metric tons (9,200 for MCC only; converting to MCC spheres increases volume)
Manufacturing vs traded volume split70% manufacturing, 25-30% traded
Gross profit percentage38%
Trading margin4-5%
Order book4,000 metric tons on hand
Premium products share of revenue13% in FY26
MCC Spheres capacity100 metric tons per month
Trade receivables₹90 crores
Purchase of stock in trade₹95 crores in FY26 P&L
Trading product split90% MCC, rest MS and cellulose powder
Trading geographic split70% domestic, 30% export
Pirana unit revenue₹153 crores in FY26
Pirana unit profit₹8.5 crores
Cash on balance sheet₹20 crores
Distributor vs direct sales split85% distributor, 15% direct
Domestic realization₹170 to ₹190 per kg
Weighted average realization₹250 to ₹260 per kg
Phase 1 peak revenue potential₹150 crores
Phase 2 peak revenue potential₹200 crores
Phase 1 expected utilization in FY2750-60%, over 9 months of production
Phase 2 expected utilization from first year75-80%
Phase 1 product realization₹600 per kg
Phase 2 product realization₹180 to ₹200 per kg
Unit 3 Phase 1 average realization₹650 to ₹700 per unit
CMC domestic selling price₹400 per kg
CMC export selling price₹800 to ₹900 per kg
CCS customer split80-90% export, remaining domestic
Expected premium product share in FY2716-17%
Phase 1 revenue as share of existing Unit 1 and 2 revenue40% at peak capacity
Industry growth: pharma and nutra6.9%
Industry growth: food and beverages5.1%
Industry growth: cosmetics5.6%
Industry growth: pet industry4.6%
Industry growth: industrial segment5.1%